[go: up one dir, main page]

WO2007079096A3 - Inhibition de protéase - Google Patents

Inhibition de protéase Download PDF

Info

Publication number
WO2007079096A3
WO2007079096A3 PCT/US2006/049322 US2006049322W WO2007079096A3 WO 2007079096 A3 WO2007079096 A3 WO 2007079096A3 US 2006049322 W US2006049322 W US 2006049322W WO 2007079096 A3 WO2007079096 A3 WO 2007079096A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibition
proteins
engineered
disclosed
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/049322
Other languages
English (en)
Other versions
WO2007079096A2 (fr
Inventor
Robert C Ladner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES06848187.8T priority Critical patent/ES2663497T3/es
Priority to JP2008548690A priority patent/JP5632126B2/ja
Priority to LTEP06848187.8T priority patent/LT1981519T/lt
Priority to DK06848187.8T priority patent/DK1981519T3/en
Priority to PL06848187T priority patent/PL1981519T3/pl
Priority to AU2006332774A priority patent/AU2006332774A1/en
Priority to CA2635589A priority patent/CA2635589C/fr
Priority to EP06848187.8A priority patent/EP1981519B1/fr
Application filed by Dyax Corp filed Critical Dyax Corp
Priority to SI200632240T priority patent/SI1981519T1/en
Publication of WO2007079096A2 publication Critical patent/WO2007079096A2/fr
Publication of WO2007079096A3 publication Critical patent/WO2007079096A3/fr
Anticipated expiration legal-status Critical
Priority to CY20181100165T priority patent/CY1119967T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention porte sur des protéines incluant des séquences artificielles inhibant les protéases, y compris les protéines incluant deux domaines de Kunitz artificiels ou plus, ainsi que les applications de telles protéines.
PCT/US2006/049322 2005-12-29 2006-12-27 Inhibition de protéase Ceased WO2007079096A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA2635589A CA2635589C (fr) 2005-12-29 2006-12-27 Inhibition de protease
LTEP06848187.8T LT1981519T (lt) 2005-12-29 2006-12-27 Proteazės slopinimas
DK06848187.8T DK1981519T3 (en) 2005-12-29 2006-12-27 protease inhibition
PL06848187T PL1981519T3 (pl) 2005-12-29 2006-12-27 Hamowanie proteaz
AU2006332774A AU2006332774A1 (en) 2005-12-29 2006-12-27 Protease inhibition
ES06848187.8T ES2663497T3 (es) 2005-12-29 2006-12-27 Inhibición de proteasas
JP2008548690A JP5632126B2 (ja) 2005-12-29 2006-12-27 プロテアーゼ阻害
EP06848187.8A EP1981519B1 (fr) 2005-12-29 2006-12-27 Inhibition de protease
SI200632240T SI1981519T1 (en) 2005-12-29 2006-12-27 INHIBITION PROTEAZE
CY20181100165T CY1119967T1 (el) 2005-12-29 2018-02-09 Αναστολη πρωτεασης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75490305P 2005-12-29 2005-12-29
US60/754,903 2005-12-29

Publications (2)

Publication Number Publication Date
WO2007079096A2 WO2007079096A2 (fr) 2007-07-12
WO2007079096A3 true WO2007079096A3 (fr) 2008-02-14

Family

ID=38228815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049322 Ceased WO2007079096A2 (fr) 2005-12-29 2006-12-27 Inhibition de protéase

Country Status (14)

Country Link
US (1) US8828703B2 (fr)
EP (1) EP1981519B1 (fr)
JP (2) JP5632126B2 (fr)
AU (1) AU2006332774A1 (fr)
CA (1) CA2635589C (fr)
CY (1) CY1119967T1 (fr)
DK (1) DK1981519T3 (fr)
ES (1) ES2663497T3 (fr)
HU (1) HUE038243T2 (fr)
LT (1) LT1981519T (fr)
PL (1) PL1981519T3 (fr)
PT (1) PT1981519T (fr)
SI (1) SI1981519T1 (fr)
WO (1) WO2007079096A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716225B2 (en) 2004-09-27 2014-05-06 Dyax Corp. Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US10385116B2 (en) 2013-01-07 2019-08-20 Omniox, Inc. Polymeric forms of H-NOX proteins

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1542710B1 (fr) 2002-08-28 2012-09-26 Dyax Corp. Procedes de conservation d'organes et de tissus
ES2447423T3 (es) * 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
EP1874798A1 (fr) * 2005-04-15 2008-01-09 Novo Nordisk A/S Etiquettes de purification de proteines basiques provenant des bacteries thermophiles
CN101563358A (zh) * 2006-10-13 2009-10-21 诺沃-诺迪斯克保健股份有限公司 融合于碱性蛋白标签的加工酶
WO2009026334A2 (fr) * 2007-08-21 2009-02-26 Genzyme Corporation Traitement par des inhibiteurs de la kallikréine
US20090105142A1 (en) * 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
EP2350305A4 (fr) * 2008-10-22 2013-03-06 Dyax Corp Polythérapie comportant des protéines de liaison de protéase pour des troubles inflammatoires
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
WO2010103475A2 (fr) * 2009-03-10 2010-09-16 Med Discovery Sa Utilisation d'inhibiteurs de sérine protéase pour le traitement d'une neutropénie
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
US9597379B1 (en) * 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
CN111044725B (zh) * 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) * 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
LT3110434T (lt) 2014-02-24 2018-12-27 Takeda Gmbh Sulieti uti baltymai
EP3122782A4 (fr) 2014-03-27 2017-09-13 Dyax Corp. Compositions et procédés pour le traitement de l'oedème maculaire diabétique
WO2016149562A2 (fr) 2015-03-17 2016-09-22 Omniox, Inc. Modulation de l'immunité tumorale par distribution d'o2 induite par une protéine
JP6903648B2 (ja) 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
CA3093802A1 (fr) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Imidazopyridines substituees en tant qu'inhibiteurs de la kallicreine plasmatique et leurs utilisations
EP4013494A1 (fr) * 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Variants du récepteur 1 de la stimulation des macrophages (mst1r) et leurs utilisations
PL4031547T3 (pl) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6333402B1 (en) * 1994-01-11 2001-12-25 Dyax Corp. Kallikrein-binding “Kunitz domain” proteins and analogues thereof
US20030114372A1 (en) * 1995-05-08 2003-06-19 White R. Tyler Protease inhibitor peptides
US20040152633A1 (en) * 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20040171794A1 (en) * 2003-02-07 2004-09-02 Ladner Robert Charles Kunitz domain peptides
US20050164945A1 (en) * 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274826B1 (fr) 1986-11-17 1998-08-12 Scios Inc. Protéine recombinante amyloide d'alzheimer
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
EP0763055B1 (fr) 1994-06-02 1999-11-03 Merrell Pharmaceuticals Inc. Inhibiteurs d'elastase au perfluoroalkyle cetone et procedes de production associes
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (de) 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
DK0891426T3 (da) * 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
US6262233B1 (en) 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
WO2001068707A1 (fr) 2000-03-13 2001-09-20 Eli Lilly And Company Homologue inhibiteur d'activateur de facteur de croissance des hepatocytes humains
JP2005512181A (ja) 2001-12-03 2005-04-28 ダイアックス、コープ ライブラリスクリーニング
WO2003066824A2 (fr) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Peptides du domaine kunitz fusionnes a l'albumine
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
AU2004266246A1 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
US20070020252A1 (en) 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
ES2447423T3 (es) 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005309722B2 (en) 2004-11-22 2011-10-20 Dyax Corp. Plasmin-inhibitory therapies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333402B1 (en) * 1994-01-11 2001-12-25 Dyax Corp. Kallikrein-binding “Kunitz domain” proteins and analogues thereof
US20030114372A1 (en) * 1995-05-08 2003-06-19 White R. Tyler Protease inhibitor peptides
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US20040152633A1 (en) * 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US20040171794A1 (en) * 2003-02-07 2004-09-02 Ladner Robert Charles Kunitz domain peptides
US20050164945A1 (en) * 2003-10-21 2005-07-28 Andrew Nixon Endotheliase-1 ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRIES ET AL.: "Inter-alpha-inhibitor, hyaluronan and inflammation", ACTA BIOCHIMICA POLONICA, vol. 50, no. 3, 2003, pages 735 - 742, XP008034612 *
MAGKLARA ET AL.: "Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors", BIOCHEM BIOPHYS RES COMMUN., vol. 307, no. 4, August 2003 (2003-08-01), pages 948 - 955, XP004439228 *
SCARFF ET AL.: "Targeted Disruption of SPl3/Serpinb6 Does Not Result in Developmental or Growth Defects, Leukocyte Dysfunction, or Susceptibility to Stroke", MOLECULAR AND CELLULAR BIOLOGY, May 2004 (2004-05-01), pages 4075 - 4082, XP008129814 *
TAGGART ET AL.: "Inactivation of Human beta-Defensins 2 and 3 by Elastolytic Cathepsins 1", THE JOURNAL OF IMMUNOLOGY, vol. 170, no. 93, 2003, pages 937, XP002495636 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716225B2 (en) 2004-09-27 2014-05-06 Dyax Corp. Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US10385116B2 (en) 2013-01-07 2019-08-20 Omniox, Inc. Polymeric forms of H-NOX proteins
US10766947B2 (en) 2013-01-07 2020-09-08 Omniox, Inc. Polymeric forms of H-NOX proteins
US11117952B2 (en) 2013-01-07 2021-09-14 Omniox, Inc. Polymeric forms of H-NOX proteins
US11987614B2 (en) 2013-01-07 2024-05-21 Omniox, Inc. Polymeric forms of H-NOX proteins

Also Published As

Publication number Publication date
CA2635589C (fr) 2017-01-17
US20080255025A1 (en) 2008-10-16
SI1981519T1 (en) 2018-05-31
DK1981519T3 (en) 2018-02-19
EP1981519A4 (fr) 2010-01-06
JP5632126B2 (ja) 2014-11-26
US8828703B2 (en) 2014-09-09
ES2663497T3 (es) 2018-04-13
EP1981519B1 (fr) 2017-12-27
AU2006332774A1 (en) 2007-07-12
EP1981519A2 (fr) 2008-10-22
CA2635589A1 (fr) 2007-07-12
JP2012235793A (ja) 2012-12-06
PL1981519T3 (pl) 2018-07-31
WO2007079096A2 (fr) 2007-07-12
CY1119967T1 (el) 2018-12-12
LT1981519T (lt) 2018-04-25
JP2009521926A (ja) 2009-06-11
HUE038243T2 (hu) 2018-10-29
PT1981519T (pt) 2018-02-23

Similar Documents

Publication Publication Date Title
WO2007079096A3 (fr) Inhibition de protéase
WO2007022459A3 (fr) Procedes et intermediaires
WO2005005679A3 (fr) Surfaces superhydrophobes, methodes de leur construction et leurs utilisations
WO2009082701A8 (fr) Inhibiteurs de hcv protéase et leurs utilisations
WO2007016476A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
WO2007092645A3 (fr) Nouvelles combinaisons d'inhibiteurs du vhc et méthodes
ATE547412T1 (de) Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
TWI348377B (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
PL373399A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2008045148A3 (fr) Procédés de criblage de protéases et protéases identifiées par lesdits procédés
WO2005047511A3 (fr) Expression bacterienne d'inhibiteurs de protease et variants de ceux-ci
PL1713822T3 (pl) Inhibitory proteazy serynowej HCV NS-3
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
WO2005007818A8 (fr) Polypeptides d'amylase exospecifiques, acides nucleiques codant lesdits polypeptides et leurs utilisations
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
WO2006127757A3 (fr) Fusion interferon-igg
TW200501277A (en) Nanofiber surfaces for use in enhanced surface area applications
WO2007016591A3 (fr) Compositions et methodes destinees a surveiller et modifier le repliement et la solubilite proteiques
WO2007025247A3 (fr) Inhibiteurs de transglutaminase et methode d'utilisation de ceux-ci
WO2008048121A3 (fr) Composés et compositions
WO2004113278A3 (fr) Inhibiteurs d'acylsulfamide de facteur viia
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
WO2003011222A3 (fr) Inhibiteurs de la thrombine
WO2007050795A3 (fr) Inhibiteurs de transglutaminase et procedes d'utilisation
NZ601647A (en) Variant hhip1 protein and methods and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2635589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008548690

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006332774

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006848187

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006332774

Country of ref document: AU

Date of ref document: 20061227

Kind code of ref document: A